Trial Profile
Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Administered as a Booster Dose in Children Vaccinated 3 Years Earlier as Toddlers
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Meningococcal vaccine groups A C Y W-135 conjugate (Primary)
- Indications Meningococcal infections
- Focus Adverse reactions; Pharmacodynamics; Registrational
- Sponsors Sanofi Pasteur
- 11 Oct 2018 Status changed from recruiting to completed.
- 26 Dec 2017 New trial record